Eisai

Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021

Friday, March 26, 2021 - 12:16am

TOKYO, Mar 26, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel (brand name: FYCOMPA, "perampanel"), the AMPA-type glutamate receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2021 by the PSJ.

Key Points: 
  • TOKYO, Mar 26, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel (brand name: FYCOMPA, "perampanel"), the AMPA-type glutamate receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2021 by the PSJ.
  • The reasons for the selection of this discovery research for the award are outlined by the PSJ as follows.
  • Although glutamate receptors, which are responsible for neuronal excitation, have long been recognized as important drug discovery targets, they have not led to the creation of any drugs.
  • It has been demonstrated that perampanel is a selective, non-competitive AMPA receptor antagonist.

Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan

Tuesday, March 23, 2021 - 9:34am

TOKYO, Mar 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.

Key Points: 
  • TOKYO, Mar 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.
  • This marks the first approval for LENVIMA for unresectable thymic carcinoma in Japan.
  • For unresectable thymic carcinoma, platinum-based first-line therapy is recommended.
  • In June 2020, LENVIMA received orphan drug designation in Japan for unresectable thymic carcinoma.

Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan

Monday, March 22, 2021 - 4:13am

The current research building at Kawashima Industrial Park has served as a base for formulation research since its completion in 1980.

Key Points: 
  • The current research building at Kawashima Industrial Park has served as a base for formulation research since its completion in 1980.
  • Most of these new modality formulations are injectable; thus the utilization of enhanced injection formulation technologies and drug delivery systems (DDSs) is essential.
  • In addition, Eisai will install an injection manufacturing facility that meets GMP* requirements, and is aiming for the in-house manufacturing of investigational injection drugs.
  • The Kawashima Industrial Park is Eisai's global pharmaceutical manufacturing base, at which Eisai has made a comprehensive framework comprising all steps from formulation research to formulation manufacturing.

Eisai Awarded The New Diversity Management Selection 100

Monday, March 22, 2021 - 1:38am

This marks the first time to be awarded ever since Eisai was included in the New Diversity Management Selection 100 Program.

Key Points: 
  • This marks the first time to be awarded ever since Eisai was included in the New Diversity Management Selection 100 Program.
  • METI has been presenting a METI Minister's Award under the New Diversity Management Selection 100 Program since its inauguration in FY 2012 with the aim of widely introducing the advanced efforts of companies that link diversity promotion to management results and encouraging companies to engage in diversity management.
  • Eisai is working on the Diversity & Inclusion as a management strategy to sustainably realize the hhc philosophy no matter how the social environment changes.
  • * For more information on Eisai's Strategy for Talents Innovation, including its initiatives toward diversity at Eisai, please see Eisai Integrated Report.

Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anti-Cancer Agent Lenvima (Lenvatinib) With Prospective Indication for Uterine Body Cancer

Friday, March 12, 2021 - 2:08am

TOKYO, Mar 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received orphan drug designation for LENVIMA (generic name: lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective indication for uterine body cancer, by the Ministry of Health, Labour and Welfare (MHLW).

Key Points: 
  • TOKYO, Mar 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received orphan drug designation for LENVIMA (generic name: lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective indication for uterine body cancer, by the Ministry of Health, Labour and Welfare (MHLW).
  • In this study, LENVIMA plus KEYTRUDA met its dual primary endpoints, overall survival (OS) and progression-free survival (PFS), as well as its secondary efficacy endpoint of objective response rate (ORR).
  • Currently, Eisai is preparing to submit an application for additional indications based on these results in various countries around the world including Japan.
  • Eisai positions oncology as a key therapeutic area and is aiming to discover innovative new medicines with the potential to cure cancer.

Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 15th International Conference on Alzheimer's and Parkinson's Disease

Friday, March 5, 2021 - 8:51am

Regarding lecanemab, preliminary analysis results of changes in brain-Aß amounts as observed in subjects of the ongoing open-label extension (OLE) of the Phase II study (Study 201) will be presented orally.

Key Points: 
  • Regarding lecanemab, preliminary analysis results of changes in brain-Aß amounts as observed in subjects of the ongoing open-label extension (OLE) of the Phase II study (Study 201) will be presented orally.
  • Lecanemab and aducanumab are being jointly developed by Eisai and Biogen.
  • In addition to presenting the latest data, Eisai and Biogen are planning to host a symposium focusing on the role of Aß in the AD pathology, entitled "The Science Behind the Aß Pathway in AD".
  • Eisai aims to realize the prevention and cure of dementia through a multi-dimensional and holistic approach with a foundation of over 35 years of experience of drug discovery activities in the area of AD and dementia.

Eisai Receives Corporate Philanthropy Award for Its Efforts to Realize Human Health Care (hhc) Philosophy

Monday, February 22, 2021 - 4:11am

The Corporate Philanthropy Award was founded in 2003 with the aim of commending companies for their activities for social contribution that organically and sustainably utilize their management resources (human resources, know-how, technology, information, etc.)

Key Points: 
  • The Corporate Philanthropy Award was founded in 2003 with the aim of commending companies for their activities for social contribution that organically and sustainably utilize their management resources (human resources, know-how, technology, information, etc.)
  • The award was presented to Eisai for its corporate philosophy of human health care (hhc) and its activities to realize the hhc philosophy, evaluating "a corporate culture and purposeful activities where employees demonstrate their true value toward the realization of a society in which people can live happily."
  • Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides, and Eisai calls this philosophy the "human health care (hhc)" philosophy, in one word.
  • Eisai will make continuous efforts, based on the hhc philosophy, to further contribute to increasing the benefits of patients and their families around the world.

H3 Biomedicine Announces Expanded Use of Real-World Evidence in Precision Medicine Research

Thursday, February 11, 2021 - 1:00pm

We already reap the benefits of our longstanding data partnership with Foundation Medicine and this agreement is a natural extension, said Lihua Yu, Ph.D., President and Chief Data Science Officer of H3.

Key Points: 
  • We already reap the benefits of our longstanding data partnership with Foundation Medicine and this agreement is a natural extension, said Lihua Yu, Ph.D., President and Chief Data Science Officer of H3.
  • We are hopeful that our collaboration with Flatiron Health and Foundation Medicine will help to accelerate the development of new precision medicines for individuals living with cancer.
  • Were very excited to be part of H3s innovative, data-driven approach to precision oncology research, said Michael Vasconcelles, M.D., Chief Medical Officer at Flatiron Health.
  • H3 Biomedicine Inc., the U.S.-based precision oncology research and development subsidiary of Eisai Co., Ltd., is solely focused on advancing drugs from bench to bedside.

Two Immigrants, One Unique Plan For A Biopharma

Tuesday, February 2, 2021 - 9:00am

"If I wanted to be a leader in biopharma, I knew I needed to become more of a generalist in my knowledge base and experience."

Key Points: 
  • "If I wanted to be a leader in biopharma, I knew I needed to become more of a generalist in my knowledge base and experience."
  • After holding senior level positions in various areas such as preclinical development, operations, and manufacturing, something interesting happened in 2011.
  • The decision was made to consolidate those four down to two, which meant closing the 20-person lab Redkar had built.
  • Eisai had decided to cut the program and were not going to make the payment to keep patent protection in place.

Eisai to Launch Parkinson's Disease Treatment Equfina in South Korea

Monday, February 1, 2021 - 12:35am

TOKYO, Feb 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has launched the Parkinson's disease treatment Equfina (safinamide mesilate, "safinamide").

Key Points: 
  • TOKYO, Feb 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has launched the Parkinson's disease treatment Equfina (safinamide mesilate, "safinamide").
  • The estimated number of patients with Parkinson's disease is approximately 150,000 in South Korea.
  • This disease is designated as a rare intractable disease in South Korea.
  • Together with providing Equfina as a new treatment option for Parkinson's disease to patients in South Korea, Eisai will make further contributions to address the diversified needs of Parkinson's disease patients and their families in Asia, and increase the benefits provided to them.